iRhythm Technologies (IRTC) Bank of America Global Healthcare Conference 2026 summary

Regulatory and market access updates

• Recent LCD update addressed key issues and expanded patient indications, improving access based on clinical and economic evidence presented.

• Advocacy and industry feedback contributed to favorable final LCD language, including systemic emboli and pre/post-TAVR indications.

Financial performance and guidance

• Q1 revenue exceeded expectations with a 3% beat and marked the sixth consecutive quarter of over 20% growth, led by Zio Monitor and strong innovative channel momentum.

• Innovative channel remains the fastest-growing segment, expected to continue outpacing other channels for the rest of the year.

• Guidance remains conservative due to tough year-over-year comps, especially in the latter half of the year, but underlying business momentum remains strong.

Margin expansion and operational efficiency

• Q1 saw significant margin outperformance, with adjusted EBITDA margin over 7% versus negative last year, driven by manufacturing automation and SG&A leverage.

• Operational leverage is supported by efficient selling models, EHR integration, and overlapping physician relationships across products.